Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408701 | 1.00 | TSHR (0.62) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL6086010 | 1.00 | TSHR (0.62) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL17416309 | 0.93 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL10033081 | 0.93 | TSHR (0.67) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL10426942 | 0.89 | TSHR (0.59) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL9860378 | 0.89 | TSHR (0.50) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL31493314 | 0.87 | TSHR (0.62) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL15994380 | 0.87 | TSHR (0.62) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL15994950 | 0.87 | TSHR (0.62) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL30998835 | 0.87 | TSHR (0.62) | TSHRHPGDALDH1A1CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376534-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4634390-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250304994-A1 | Circular RNA Compositions and Methods | ORNA THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250283073-A1 | Circular RNA Compositions and Methods | ORNA THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12297285-B2 | Circular RNA encoding chimeric antigen receptors targeting BCMA | ORNA THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4543912-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | Orna Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240245805-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4121453-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022261490-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022251665-A1 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220323480-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3920976-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021236855-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021189059-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200368254-A1 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | TRUSTEES OF TUFTS COLLEGE | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283073-A1 | Circular RNA Compositions and Methods | U2AF1, RBM17, RBM22 | TSHR 3314/4885HPGD 4592/4885ALDH1A1 3618/4885 |
| US-20250376534-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | RBM17, BCR, BCDIN3D | TSHR 1378/4885HPGD 4784/4885ALDH1A1 3919/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | TSHR 2825/4885HPGD 3708/4885ALDH1A1 4876/4885 |
| US-12297285-B2 | Circular RNA encoding chimeric antigen receptors targeting BCMA | RBM17, BCR, BCDIN3D | TSHR 1378/4885HPGD 4784/4885ALDH1A1 3919/4885 |
| US-20240245805-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | AGO2, U2AF1, RBM22 | TSHR 2216/4885HPGD 4025/4885ALDH1A1 4065/4885 |
| US-20220323480-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | TSHR 1491/4885HPGD 4102/4885ALDH1A1 4484/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | TSHR 2825/4885HPGD 3708/4885ALDH1A1 4876/4885 |
| US-20200368254-A1 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | APOB, LDLR, LIPA | TSHR 2380/4885HPGD 4027/4885ALDH1A1 3888/4885 |
| US-20250304994-A1 | Circular RNA Compositions and Methods | U2AF1, RBM22, RTCB | TSHR 3293/4885HPGD 4369/4885ALDH1A1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.